EP4727533A2 - Synthese von 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminiumsalzen - Google Patents

Synthese von 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminiumsalzen

Info

Publication number
EP4727533A2
EP4727533A2 EP24824240.6A EP24824240A EP4727533A2 EP 4727533 A2 EP4727533 A2 EP 4727533A2 EP 24824240 A EP24824240 A EP 24824240A EP 4727533 A2 EP4727533 A2 EP 4727533A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
aspects
cps
mosm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824240.6A
Other languages
English (en)
French (fr)
Inventor
Tim GRINSTEAD
J. Gregory Reid
Hoi Lun Allan Tse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visus Therapeutics Inc
Original Assignee
Visus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visus Therapeutics Inc filed Critical Visus Therapeutics Inc
Publication of EP4727533A2 publication Critical patent/EP4727533A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP24824240.6A 2023-06-16 2024-06-14 Synthese von 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminiumsalzen Pending EP4727533A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508601P 2023-06-16 2023-06-16
PCT/US2024/034043 WO2024259258A2 (en) 2023-06-16 2024-06-14 Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts

Publications (1)

Publication Number Publication Date
EP4727533A2 true EP4727533A2 (de) 2026-04-22

Family

ID=93852772

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824240.6A Pending EP4727533A2 (de) 2023-06-16 2024-06-14 Synthese von 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminiumsalzen

Country Status (7)

Country Link
EP (1) EP4727533A2 (de)
KR (1) KR20260023579A (de)
CN (1) CN121548413A (de)
AU (1) AU2024303954A1 (de)
CO (1) CO2026000384A2 (de)
IL (1) IL325309A (de)
WO (1) WO2024259258A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129348T1 (de) * 1989-10-13 1995-11-15 Biocompatibles Ltd Verfahren zur verminderung der absetzung von proteinen auf ophthalmologische geräte.
EP3522873B1 (de) * 2016-10-04 2022-03-16 Cellix Bio Private Limited Zusammensetzungen und verfahren zur behandlung von xerostomie

Also Published As

Publication number Publication date
KR20260023579A (ko) 2026-02-20
CO2026000384A2 (es) 2026-02-02
IL325309A (en) 2026-02-01
WO2024259258A3 (en) 2025-06-12
AU2024303954A1 (en) 2026-01-29
WO2024259258A2 (en) 2024-12-19
CN121548413A (zh) 2026-02-17

Similar Documents

Publication Publication Date Title
KR100467898B1 (ko) 티아졸리딘의 제조 방법
AU2024203511A1 (en) Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof
JP3215338B2 (ja) アミノベンゼンスルホン酸誘導体一水和物及びその製造方法
AU2024303954A1 (en) Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts
US8637515B2 (en) Polymorphs of brimonidine pamoate
WO2019218864A1 (zh) 一种2-(α羟基戊基)苯甲酸的有机胺酯衍生物药物
US9580414B2 (en) Salts and hydrates of antipsychotics
Marzoni et al. 6-Methylergoline-8-carboxylic acid esters as serotonin antagonists: N1-substituent effects on 5HT2 receptor affinity
NO165144B (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av interne salter av aminopyridiniumhydroksidog deres tilsvarende salter.
US12583835B2 (en) Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof
US11142501B2 (en) Prodrugs of monomethyl fumarate
EP2599772B1 (de) Herstellungsverfahren für eine aminoalkyl-thioschwefelsäure-verbindung
US20090069568A1 (en) Method for producing indazol-3-ylmethyl phosphonium salt
FI59595B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5 eller 6-trifluormetyl 3-(4-alkylpiperazin-1-yl)karbonyloxi-2-(1,8-naftyridin-2-yl)isoindolin-1-oner
US20250206723A1 (en) Methods and processes for the preparation of mct4 inhibitors
WO2023122842A1 (es) Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
AU2022242950A1 (en) Process for preparation of cabozantinib
HK40076636B (zh) 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用
US20070099974A1 (en) (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition
JP2001316381A (ja) アミノベンゼンスルホン酸誘導体一水和物及びその製造方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR